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6/j.bThis single-center retrospective study analyzed 85 consecutive patients who underwent allogeneic stem cell
transplantation (allo-SCT) with the aim to assess whether there is a correlation between exposure to cyclo-
sporine-A (CsA; as measured by CsA concentrations during the first month after allo-SCT) and the risk for
developing severe grade III-IV acute graft-versus-host disease (aGVHD). The median concentrations of CsA
in the blood at 1, 2, 3, and 4 weeks after allo-SCTwere 348 (range: 172-733), 284 (range: 137-535), 274
(range: 107-649), and 247 (range: 37-695) ng/mL, respectively. Overall, grade II-IV aGVHD occurred in 36
patients (42%) at a median of 29 (range: 6-100) days after allo-SCT. The incidence of grade III-IV aGVHD
(n 5 20) was 23% (95% confidence interval [CI], 14%-32%). In univariate analysis, patients receiving allo-
SCT from an HLA-matched unrelated donor had a higher risk of grade III-IV aGVHD, and patients having
the lowest CsA concentration in the first and second weeks after allo-SCT had a significantly higher risk
of grade III-IV aGVHD. In a multivariate logistic regression analysis, a higher CsA concentration measured
during the first week following graft infusion was the strongest parameter significantly associated with a re-
duced risk of severe grade II-IV aGVHD (P 5 .012; relative risk [RR] 5 0.24; 95% CI, 0.08-0.73). Of note,
when adjusted by donor type, CsA concentration in week 1 remained significantly associated with risk of
severe grade II-IV aGVHD (P 5 .014). We conclude that precise monitoring of CsA concentrations and
adjustment of CsA dose early after allo-SCT may be effective to prevent onset of severe aGVHD.
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Allogeneic hematopoietic stem cell transplantation
(allo-SCT) is an effective therapy for different life-
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bmt.2009.08.010limited by the immunologic recognition and destruc-
tion of host tissues, termed graft-versus-host disease
(GVHD). Both in its acute and chronic forms
(aGVHD, cGVHD), it continues to be the major
source of morbidity and mortality following allo-
SCT [1]. Thus, the feasibility of allo-SCT owes
much to improvements in the immunosuppressive reg-
imens that prevent or control GVHD. The introduc-
tion of Cyclosporine-A (CsA) in the early 1980s for
GVHD prophylaxis led to a dramatic decrease of
GVHD-related morbidity and mortality after allo-
SCT [2]. In recent years, a number of newer
immunosuppressants (tacrolimus, mycophenolate
mofetil, sirolimus, etc.) have entered clinical practice
[3–6]. However, despite these developments, the com-
bination of CsA and methotrexate (MTX) remains the
standard approach for GVHD prophylaxis in a majority
of transplant centers. Different clinical risk factors for
aGVHD have been identified (eg, age, donor-recipient
sex, cytomegalovirus [CMV] serostatus, ABO compat-
ibility, diagnosis, disease status, stem cell source, donor
Biol Blood Marrow Transplant 16:28-34, 2010 29Cyclosporine Concentration and Acute GVHDtype, conditioning regimen type, GVHD prophylaxis
regimen, etc.) [7]. Accordingly, there is now a develop-
ing interest in tailoring the intensity and duration of
posttransplant immunosuppression according to the
perceived risk of GVHD and disease relapse in an indi-
vidual patient [8]. In addition, based on strategies uti-
lized in recipients of solid organ transplants, there is
an increased awareness of the impact of the intensity
of posttransplant immunosuppression on determining
outcome. So far, CsA has been the most commonly
used agent for GVHD prophylaxis after allo-SCT. Pre-
vious studies in the myeloablative allo-SCT setting have
demonstrated that low CsA concentrations can be
a cause of increased risk of aGVHD [9–11]. Other stud-
ies from the 1990s have also demonstrated an inverse
relation between trough CsA levels and incidence of
GVHD [12,13]. In the current study, which assessed pa-
tients treated more recently, including patients receiv-
ing so-called reduced-intensity or nonmyeloablative
conditioning (RIC, NMA) regimens prior to allo-
SCT, we retrospectively analyzed the data of 85 consec-
utive patients who underwent allo-SCT with the aim to
assess whether there is a correlation between exposure to
CsA (as measured by CsA concentrations early after
allo-SCT) and the risk for developing severe grade III-
IV aGVHD.PATIENTS AND METHODS
Eighty-five consecutive patients who received allo-
SCT between 2006 and 2008 at the University Hospi-
tal of Nantes (CHU de Nantes, Nantes, France) were
included in this retrospective single-center study. The
primary endpoint of the study was to determine the
relation between the serum CsA concentration and
the risk of severe grade III-IV aGVHD. For the pur-
pose of this analysis, all patients who received either
standard myeloablative (MA) or RIC allo-SCT were
included. In our transplant program, eligibility criteria
for RIC allo-SCT that preclude the use of standard
MA allo-SCT include: (1) patient age older than 50
years; (2) heavily pretreated patients who received
auto-SCT or with more than 2 lines of chemotherapy
before allo-SCT; and (3) patients with poor perfor-
mance status because of significant medical comorbid-
ities [14]. Written informed consent was obtained
from each patient and donor. The study was approved
by the local institutional review board. All allogeneic
grafts were obtained from HLA-A, HLA-B, HLA-C,
HLA-DR, and HLA-DQ-matched donors. A single
HLA mismatched of 10 (at HLA-C) was allowed at
the allele level. HLA-DP typing was not routinely per-
formed at time of this study. All donor/recipient pairs
were typed at the allelic level. They were first typed at
the 2-digit level for HLA class I (HLA-A, HLA-B, and
HLA-Cw) and class II (HLA-DRB1 and HLA-DQB1)
using published HLA class I polymerase chain reactionsequence-specific oligonucleotide (PCR-SSO) and/or
PCR-sequence-specific primers (PCR-SSP) typing
protocols. HLA typing was performed according to
the recommendations of the European Federation
for Immunogenetics (EFI) Histocompatibility Labo-
ratory standards during the study period.
Patients, donors, and transplant characteristics
are summarized in Table 1. All patients received the pre-
parative regimen as inpatients in private rooms, and
remained hospitalized until hematopoietic and clinical
recovery. Thirty-seven donors (43.5%) were HLA-
identical sibling donors, whereas 48 (46.5%) were
HLA-unrelated donors (MUD). The stem cell source
was bone marrow (BM) in 19 cases (22%) and granulo-
cyte-colony stimulating factor (G-CSF)-mobilized pe-
ripheral blood stem cells (PBSCs) in 66 cases (78%).
The MA preparative regimen included the classical cy-
clophosphamide (Cy; 120 mg/kg) combined with total
body irradiation (TBI; 12 Gy; n5 19) or with busulfan
(Bu; 16 mg/kg; n5 3). Patients receiving MA regimens
did not receive antithymocyte globulins (ATG) aspart of
the conditioning regimen. Patients with aplastic anemia
received Cy and ATG (n 5 2). Fifty-one patients from
the RIC group received fludarabine (Flu) 30 mg/m2
for 5 or 4 consecutive days, busulfan (Bu; equivalent to
8 mg/kg total dose, substituted with treosulfan or mel-
phalan [Mel] in 5 cases), and ATG (Thymoglobulin;
Genzyme, Lyon, France) 5 mg/kg total dose [14]. Five
patients received fludarabine 30 mg/m2 for 3 days and
low-dose (2 Gy) TBI. Finally, 5 patients received the
FLAMSA regimen with TBI being replaced by Bu 16
mg/kg [15]. Supportive care and antimicrobial prophy-
laxis were reported previously [16]. For GVHD prophy-
laxis, the MA allo-SCT group received CsA and short-
course methotrexate (MTX; 15 mg/m2 at day 1, 10
mg/m2 at days 3 and 6) [2]. Patients from the RIC group
received either CsA alone in case of ATG-based RIC
and an HLA-sibling donor [14] or CsA and mycopheno-
late mofetil (MMF) in case of an HLA-MUD.
In this series, CSA was administered at a dose of 3 mg/
kg/day by continuous intravenous infusion starting
from day23 or22, and changed to twice daily oral dos-
ing as soon as tolerated. CsA blood trough concentra-
tions were monitored 3 times per week during the
intravenous treatment and at least once per week after
switch to oral dosing. Trough levels of CsA were
assessed by radioimmunoassay (RIA) using commer-
cially available kits (Immunotech, Beckman-Coulter,
France) according to the manufacturer procedures.
Blood samples were collected early in the morning.
For the purpose of this analysis, the mean weekly con-
centration of CsA was calculated for each patient using
the different concentrations measured during a defined
week. CsA doses were adjusted to achieve blood levels
between 150 and 250 ng/mL and to prevent renal
dysfunction. MMF was given at a fixed oral dose of 1 g
 2/day. No treatment adjustment was performed for
Table 1. Study Population Characteristics
Characteristic (%) Study Population (N585)
Patient age, median (range) 51 (18-67)
Patient sex
Male 45 (53)
Female 40 (47)
Donor sex
Female donor 46 (54)
CMV serologic status
Seronegative donor-recipient pair 36 (42)
ABO mismatch 28 (33)
Diagnosis*
Myeloid malignancies 33 (39)
Lymphoid malignancies 49 (58)
Aplastic anemia 3 (3)
Disease status†
Standard risk 46 (54)
High risk 39 (46)
Stem cell source
Bone marrow 19 (22)
PBSC 66 (78)
Donor type
Matched related donor (MRD) 37 (43.5)
Matched unrelated donor (MUD) 48 (56.5)
Conditioning regimen category
Myeloablative conditioning (MAC) 24 (28)
Reduced intensity conditioning (RIC) 61 (72)
GVHD prophylaxis
CsA alone 31 (36)
CsA + MMF 32 (38)
CsA + MTX 22 (26)
CsA blood concentrations during the first week
after allo-SCT, median (ng/mL; range)
348 (172-733)
CsA blood concentrations during the second
week after allo-SCT, median (ng/mL; range)
284 (137-535)
CsA blood concentrations during the third
week after allo-SCT, median (ng/mL; range)
274 (107-649)
CsA blood concentrations during the fourth
week after allo-SCT, median (ng/mL; range)
247 (37-695)
Acute GVHD indicates acute graft-versus-host disease; CsA, cyclospo-
nine-A; allo-SCT, allogeneic stem cell transplantation; MMF, mycopheno-
late mofetil; MTX, methotrexate; CMV, cytomegalovirus; PBSCs,
peripheral blood stem cells.
*Myeloid malignancies: 25 acute myelogenous leukemia (AML), 5 myelo-
dysplastic syndrome (MDS), 2 chronic myelogenous leukemia (CML),
and 1 myeloproliferative syndrome (MP)S; lymphoid malignancies: 23
non-Hodgkin’s lymphoma (NHL), 8 acute lymphoblastic leukemia
(ALL), 7 Hodkin disease, 6 chronic lymphocytic leukemia (CLL), 4 mul-
tiple myeloma, and 1 prolymphocytic leukemia.
†Patients in complete remission, chronic phase, or untreated were con-
sidered as standard risk; all others were considered as high risk.
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Figure 1. (A) CsA values at weekly intervals post allo-SCT (box and
whisker plots are displayed, showing theminimum, first quartile, median,
third quartile, and maximum, outliers are denoted by 1). (B) OS, re-
lapse, and TRM in the whole study population.
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60 and CsA from day 90 if no GVHD appeared. Of note,
during the whole study period supportive care was the
same. CMV infection management was also homoge-
neous. All blood products were filtered irradiated and
CMV screened. In the first 100 days post-allo-SCT, pa-
tients were assessed at least once per week for CMV re-
activation by PCR assay to initiate preemptive
ganciclovir therapy. aGVHD was evaluated according
to the Seattle standard criteria.
The probability of overall survival (OS) was calcu-
lated by the Kaplan-Meier method. Comparison of the
groups, with and without severe grade III-IV aGVHD,
was carried out using the chi-squared test for categoricvariables, and the t-test for continuous data. Variables
with values of P\ .10 were entered into a multivariate
logistic regression analysis. Probabilities of relapse and
treatment-related mortality (TRM) were calculated
using the cumulative incidence procedure. Probabili-
ties of developing aGVHD were also calculated using
the cumulative incidence procedure, with death remis-
sion considered as the competing event. SPSS v16 and
R were used for all statistical analyses.RESULTS
In this series, the median age was 51 (range: 18-67)
years, with 46 patients (54%) receiving a graft from a fe-
male donor. Thirty-three patients (39%) had a myelog-
enous malignancy, 49 (58%) had a lymphogenous
malignancy, and 3 patients had severe aplastic anemia
(SAA). All patients engrafted at a median of 17 (range:
0-42) days after allo-SCT. The median concentrations
of CSA in the blood at 1, 2, 3, and 4 weeks after allo-
SCT were 348 (range: 172-733), 284 (range: 137-
535), 274 (range: 107-649), and 247 (range: 37-695)
ng/mL, respectively (Figure 1A). In this series, the me-
dian follow-up was 16 (range: 5-29) months and the OS,
relapse, and TRM rates at 1 year after allo-SCT were
Table 2. Univariate Analysis of Risk Factors for Severe Acute
GVHD Development
Characteristic (%)
Patients with No or
Grade 1-II Acute
GVHD (n565)
Patients with
Grade III-IV Acute
GVHD (n520) P
Patient age, median (range) 51 (18-67) 51 (25-65) .97
Patient sex
Male 34 (52) 11 (55) .83
Female 31 (48) 9 (45)
Donor sex
Female donor 36 (55) 10 (50) .67
CMV serologic status
Seronegative donor-
recipient pair
26 (40) 10 (50) .43
ABO mismatch 19 (29) 9 (45) .19
Diagnosis
Myeloid malignancies 24 (37) 9 (45)
Lymphoid malignancies 39 (60) 9 (45) .61
Aplastic anemia 2 (3) 1 (5)
Disease status
Standard risk 36 (55) 10 (50) .67
High risk 29 (45) 10 (50)
Stem cell source
Bone marrow 14 (21.5) 5 (25) .99
PBSC 51 (78.5) 15 (75)
Donor type
Matched related
donor (MRD)
32 (49) 5 (25) .056
Matched unrelated
donor (MUD)
33 (51) 15 (75)
Conditioning regimen
category
Myeloablative
conditioning (MAC)
16 (25) 8 (40) .18
Reduced intensity
conditioning (RIC)
49 (75) 12 (60)
GVHD prophylaxis
CsA alone 25 (38.5) 6 (30)
CsA + MMF 25 (38.5) 7 (35) .56
CsA + MTX 15 (23) 7 (35)
CsA blood concentrations
during the first week
after allo-SCT, median
(ng/mL; range)
361 (172-733) 310 (193-543) .011
CsA blood concentrations
during the second week
after allo-SCT, median
(ng/mL; range)
292 (137-535) 250 (174-384) .024
CsA blood concentrations 276 (107-522) 241 (113-649) .51
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The incidence of cGVHD was 27%, and there was no
correlation between CsA concentrations after allo-
SCT and the occurrence of cGVHD (P 5 .44). Also,
we did not find a statistically significant correlation in
terms of OS, relapse incidence, or TRM between pa-
tients having the highest CsA concentrations in the first
week after allo-SCT compared to patients with lower
CsA concentrations. Overall, grade II-IV aGVHD oc-
curred in 36 patients (42%) at a median of 29 (range:
6-100) days after allo-SCT. The incidence of severe
grade 3-4 aGVHD (n5 20) was 23% (95% confidence
interval [CI], 14%-32%). Univariate analysis of risk fac-
tors for severe aGVHD (grade III-IV) development is
shown in Table 2. Patients receiving allo-SCT from
an HLA-matched unrelated donor had a higher risk of
grade 3-4 aGVHD. In addition, patients having the
lowest CSA concentration in the first and second weeks
after allo-SCT had a significantly higher risk of grade
III-IV aGVHD (Figure 2A and B). Of note, there was
a statistical trend toward a significant association be-
tween grade II-IV aGVHD and CsA concentration in
the first week after allo-SCT (median: 379 ng/mL for
patients without grade II-IV aGVHD versus 326 ng/
mL for patients developing grade II-IV aGVHD; P 5
.06). In a multivariate logistic regression analysis (Table
3), we found that higher CsA concentration ($348 ng/
mL; the median CsA concentration during the first
week in the whole study population is used to segregate
the patients between low and high CsA concentrations)
during the first week following graft infusion, and be-
fore onset of aGVHD was the strongest parameter sig-
nificantly associated with a reduced risk of severe grade
III-IV aGVHD (P 5 .012; RR 5 .24; 95% CI, 0.08-
0.73). Of note, when adjusted by donor type (P 5
.073), CsA concentration in week 1 remained
significantly associated with risk of severe grade III-IV
aGVHD (P 5 .014).during the third week
after allo-SCT, median
(ng/mL; range)
CsA blood concentrations
during the fourth week
after allo-SCT, median
(ng/mL; range)
238 (37-695) 277 (116-413) .77
Acute GVHD indicates acute graft-versus-host disease; CSA, cyclospo-
nine-A; allo-SCT, allogeneic stem cell transplantation; MMF, mycopheno-
late mofetil; MTX, methotrexate; CMV, cytomegalovirus; PBSCs,
peripheral blood stem cells.DISCUSSION
More than 20 years ago, the Seattle group demon-
strated that low CsA concentrations can be a cause of
increased risk of aGVHD, and that concentrations
should be monitored in recipients of BM transplant
(BMT) recipients [9]. In the latter study, Yee et al.
[10,11] reported a relative risk of 0.7 for every increase
of 100 ng/mL for the CsA concentration. The same
held true in the pediatric population transplanted
from a matched-sibling or an unrelated donor, where
low trough CsA blood concentration was a major
risk factor for severe aGVHD. Other studies from
the early 1990s have also demonstrated an inverse
relation between trough CsA levels and incidence of
GVHD [12,13]. In addition, early studies from the
solid organ transplantation field already suggestedthat trough CsA concentrations correlated with clini-
cal outcomes, both in terms of rejection and nephro-
toxicity [17], and also that the correlation with
trough levels was better than with the maximum
concentration [18].
Despite significant improvement in terms of sup-
portive care and HLA matching, results from the
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Figure 2. (A) Cumulative incidence of grade III-IV aGVHD according to
CSA level during the first week after allo-SCT (the median CsA concen-
tration during the first week in the whole study population is used to
segregate the 2 groups). (B) Cumulative incidence of grade III-IV aGVHD
according to CsA level during the second week after allo-SCT (the me-
dian CsA concentration during the secondweek in thewhole study pop-
ulation is used to segregate the 2 groups).
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tween 2006 and 2008, still suggest a close relationship
between CsA trough blood concentration during the
early post allo-SCT period and the risk of severe grade
III-IV aGVHD. This is in accordance with other re-
cent data from Oshima et al. [19] showing that contin-
uous CsA infusion with a high target level (450-550
ng/mL) can decrease the incidence of aGVHD.Table 3. Results of the Multivariate Logistic Analysis to Find
Prognostic Factors for Grade III-IV Acute GVHD
Variable
No. of
Patients Odds Ratio 95% CI P Value
CsA blood concentration
during 1st week after
allo-SCT
<348 ng/mL 43 1.00
>348 ng/mL 42 0.24 (0.08-0.75) .014
Donor type
Matched related donor 37 1.00
Matched unrelated donor 48 2.90 (0.91-9.3) .073
CsA indicates cyclosporine-A; allo-SCT, allogeneic stem cell transplanta-
tion; CI, confidence interval; GVHD, graft-versus-host disease.
Included in this analysis were: CsA blood concentration during weeks 1
and 2, and donor type. In the backward stepping procedure, only the
above 2 variables remained in the model.However, the decreased incidence of severe grade
III-IV aGVHD did not translate into a statistically sig-
nificant advantage in terms of OS, TRM, or relapse.
This might be because of the relatively limited size
of our study population, or the heterogeneity of the
different disease entities that were included. Another
explanation may rely in the fact that low CsA doses
can be associated with a significant reduction of disease
relapse, probably because of an increased graft-versus-
leukemia (GVL) effect, counterbalancing the overall
deleterious impact of severe aGVHD, as previously
shown in adults and children with acute leukemia given
HLA-identical sibling BMT [20,21]. However, as
highlighted recently in a consensus statement by
Martin et al. [22], it is important to note that in the
field of aGVHD, although improved survival would
provide persuasive evidence of benefit, experience
has shown that this does not necessarily lead to im-
proved survival. For example, a study by Levine et al.
[23] showed that despite impressive differences in re-
sponse rates after treatment of aGVHD with etaner-
cept plus steroids compared to steroids alone,
survival differences were observed among patients
who had related donors, but not among those with un-
related donors. Indeed, differences in the magnitude of
response and survival effects are likely related to com-
plications such as infection, regimen-related toxicity,
recurrent malignancy, and preexisting conditions un-
related to GVHD. Another weakness of the current
study is its retrospective nature and the limitations of
just evaluating mean weekly trough levels of CSA in-
stead of areas under the curve (AUC). Also, parameters
such as age, different GVHD-prophylaxis and condi-
tioning regimens, type of donor (related versus unre-
lated), stem cell sources may represent confounding
factors.
From the pathophysiologic standpoint, CsA exerts
its immunosuppressive effects through suppression of
calcineurin-mediated T-lymphocyte activation and ac-
cumulating evidence demonstrates that peak levels of
CsA correlate best with the degree of calcineurin inhi-
bition achieved [24]. Interestingly, it has been already
reported that the risk of aGVHD correlates with the
degree of calcineurin inhibition in the mononuclear
cells of patients in the first 2 months posttransplant
[25]. However, this important observation still re-
quires validation in a larger cohort of patients. In addi-
tion, CsA pharmacokinetics are highly variable, with
factors such as donor type, patient age,and especially
concurrent drug therapy all influencing trough blood
concentrations of the drug [26]. Therefore, several
factors determining peak as well as trough levels of
CsA can have a significant impact on the degree of
CsA-mediated immunosuppression after allo-SCT.
Given this marked variability in CsA pharmacokinet-
ics, blood-level monitoring has for many years been
the standard practice for patients receiving CsA in
Biol Blood Marrow Transplant 16:28-34, 2010 33Cyclosporine Concentration and Acute GVHDthe solid organ transplant and allo-SCT settings [27].
However, despite its widespread usage, there has re-
mained a degree of uncertainty as to whether this
approach is the most appropriate way of performing
drug monitoring of CsA. Indeed, some authors have
failed to demonstrate a significant relationship be-
tween trough concentrations and aGVHD [28-30],
and conflicting findings have also been reported
when studying the association between CsA levels
and the risk of nephrotoxicity [30–32]. These concerns
generated increased interest in developing alternative
monitoring strategies for CsA. This led to the develop-
ment of sparse-sampling algorithms [33], which used 2
or 3 time points as surrogate markers for exposure to
CsA and were found to correlate with AUC. A number
of studies showed that a sample taken 2 hours after an
oral dose of CsA (C2) was the most accurate single
marker of exposure [34,35]. The demonstration that
calcineurin inhibition correlated well with CsA levels,
with maximal inhibition occurring during the period
of highest CsA concentration [24], provided a further
pharmacodynamic argument for utilizing C2 monitor-
ing in the posttransplant setting, and some authors con-
cluded that C2 monitoring is the optimal method of
monitoring oral CsA in the setting of de novo renal
and liver transplants [36]. As a result, there is now inter-
est in examining whether there is scope for translating
these advances into the arena of allo-SCT. Indeed, in
the context of standard MA allo-SCT, Izumi et al.
[37] have recently shown that higher C5 (CsA concen-
tration at 5 hours after the start of infusion) reduced
the incidence of grades II-IV aGVHD. At present, there
is a mounting need to reexamine the current schedules
for dosing and monitoring CsA after allo-SCT. This
is particularly of high importance in the setting of
RIC allo-SCT, where modulation of the graft-versus-
tumor effect plays a critical role. A survey of 87 centers
by the European Blood and Marrow Transplant
(EBMT) showed inconsistency in both timing of CsA
infusion and variations in the range of dose. There
was also a lack of standardization in assay techniques
used for measurement [38]. Because relapse remains
the major cause of treatment failure after RIC allo-
SCT, controlled studies examining both the dose
intensity (and whether peak-level monitoring may be
superior to trough-level monitoring both for intrave-
nous [i.v.] and oral CsA) and duration of CsA
administration are needed [39].
Although one must acknowledge that clinical obsta-
cles such as renal failure, drug interactions, and pharma-
codynamics of CsA may preclude early achievement of
high CsA levels, we conclude that data from the current
study indicate a close relationship between CsA trough
blood concentration during the early post-allo-SCT
period and the severity of aGVHD. Inadequate or insuf-
ficient early exposures of CsA can be a serious risk for
developing severe aGVHD. Therefore, achievementof a high CsA target concentration may be an effective
tool to prevent the onset of severe aGVHD. The latter
needs to be tested in a prospective fashion at a larger
scale, because the rapidly increasing use in elderly and
high risk patients and evolving nature of allo-SCT em-
phasizes the need for renewed clinical research of
GVHD prophylaxis that may have a significant impact
on the probability of a favorable outcome.ACKNOWLEDGMENTS
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